Asunto(s)
Enfermedad Injerto contra Huésped/complicaciones , Infarto de la Pared Inferior del Miocardio/etiología , Adolescente , Anemia Aplásica/complicaciones , Angioplastia , Trasplante de Médula Ósea/efectos adversos , Femenino , Enfermedad Injerto contra Huésped/tratamiento farmacológico , Humanos , Infarto de la Pared Inferior del Miocardio/terapia , Síndromes Mielodisplásicos/complicaciones , Síndromes Mielodisplásicos/terapia , Stents , Resultado del TratamientoRESUMEN
Interleukin-10 (IL-10) ameliorates various T-helper type 1 cell-mediated chronic inflammatory diseases. Although the therapeutic benefits of IL-10 include antiatherosclerotic effects, pathophysiological effects of IL-10 on vascular remodeling in hypertension have not yet been elucidated. These studies were designed to determine whether sustained IL-10 expression, mediated by an adeno-associated virus (AAV) vector, prevents vascular remodeling and target-organ damage in the stroke-prone spontaneously hypertensive rat (SHR-SP)-an animal model of malignant hypertension. A single intramuscular injection of an AAV1 vector encoding rat IL-10 introduced long-term IL-10 expression. These IL-10-transduced rats had decreased stroke episodes and proteinuria, resulting in improved survival. Histological examination revealed a reduced level of deleterious vascular remodeling of resistance vessels in the brain and kidney of these rats. Immunohistochemical analysis indicated that IL-10 inhibited the enhanced renal transforming growth factor-beta expression and perivascular infiltration of monocytes/macrophages and nuclear factor-kappaB-positive cells normally observed in the SHR-SP. Four weeks after IL-10 vector injection, systolic blood pressure significantly decreased and this effect persisted for several months. Overall, AAV vector-mediated systemic IL-10 expression prevented vascular remodeling and inflammatory lesions of target organs in the SHR-SP. This approach provides significant insights into the prevention strategy of disease onset with unknown genetic predisposition or intractable polygenic disorders.
Asunto(s)
Terapia Genética/métodos , Hipertensión/complicaciones , Interleucina-10/biosíntesis , Accidente Cerebrovascular/prevención & control , Animales , Presión Sanguínea/fisiología , Encéfalo/irrigación sanguínea , Encéfalo/patología , Arterias Carótidas/patología , Dependovirus/genética , Vectores Genéticos , Hipertensión/metabolismo , Hipertensión/patología , Interleucina-10/genética , Enfermedades Renales/etiología , Enfermedades Renales/patología , Enfermedades Renales/prevención & control , Masculino , Ratas , Ratas Endogámicas SHR , Accidente Cerebrovascular/etiología , Accidente Cerebrovascular/patología , Análisis de Supervivencia , Transducción GenéticaRESUMEN
OBJECTIVE: CD34-positive bone marrow mononuclear cells (MNCs) have been successfully used for regeneration of small arteries in Buerger's disease. The objective of this study is to examine the angiogenetic potential of autologous MNCs from bone marrow and peripheral blood implanted into the ischaemic digits from patients with connective tissue diseases. METHODS: Three patients with systemic sclerosis, two with mixed connective tissue disease, and one with CREST syndrome were enrolled who had painful ischaemic digits with necrosis refractory to several vasodilators including intravenous prostaglandins. MNCs obtained from 7 ml/kg bone marrow blood and 400 ml peripheral blood were implanted into 20 different sites in palms and/or soles. The study was performed open-labelled. RESULTS: Pain in the numeric rating scale improved remarkably up to 1 month after implantation of bone marrow or peripheral MNCs to the same extent, although no significant differences were found in transcutaneous oxygen pressure and thermogram before and after the implantation. Bone marrow MNCs increased blood flow of the hand determined by intra-arterial digital subtraction angiography, while peripheral MNCs did not. CONCLUSIONS: Implantation of autologous MNCs from peripheral and bone marrow into the ischaemic digits was so effective in pain-relief and more clinical trials would be warranted to see whether this could be a new treatment modality for angiogenesis in connective tissue diseases as in Buerger's disease.
Asunto(s)
Trasplante de Médula Ósea , Enfermedades del Tejido Conjuntivo/terapia , Isquemia/terapia , Trasplante de Células Madre de Sangre Periférica , Anciano , Angiografía de Substracción Digital , Antígenos CD34/análisis , Síndrome CREST/terapia , Enfermedades del Tejido Conjuntivo/complicaciones , Femenino , Dedos/irrigación sanguínea , Humanos , Isquemia/diagnóstico por imagen , Isquemia/etiología , Masculino , Persona de Mediana Edad , Neovascularización Fisiológica , Dedos del Pie/irrigación sanguínea , Resultado del TratamientoAsunto(s)
Fístula Arterio-Arterial/diagnóstico por imagen , Cardiomiopatías/diagnóstico por imagen , Anomalías de los Vasos Coronarios/diagnóstico por imagen , Fístula/diagnóstico por imagen , Fístula Vascular/diagnóstico por imagen , Angiografía Coronaria/métodos , Dilatación Patológica/diagnóstico por imagen , Femenino , Aneurisma Cardíaco/diagnóstico por imagen , Ventrículos Cardíacos/diagnóstico por imagen , Humanos , Persona de Mediana EdadRESUMEN
Inflammation is a major contributor to atherosclerosis by its effects on arterial wall biology and lipoprotein metabolism. Interleukin-10 (IL-10) is an anti-inflammatory cytokine that may modulate the atherosclerotic disease process. We investigated the effects of adeno-associated virus (AAV) vector-mediated gene transfer of IL-10 on atherogenesis in apolipoprotein E (ApoE)-deficient mice. A murine myoblast cell line, C2C12, transduced with AAV encoding murine IL-10 (AAV2-mIL10) secreted substantial amounts of IL-10 into conditioned medium. The production of monocyte chemoattractant protein-1 (MCP-1) by the murine macrophage cell line, J774, was significantly inhibited by conditioned medium from AAV2-mIL10-transduced C2C12 cells. ApoE-deficient mice were injected with AAV5-mIL10 into their anterior tibial muscle at 8 weeks of age. The expression of MCP-1 in the vascular wall of the ascending aorta and serum MCP-1 concentration were decreased in AAV5-mIL10-transduced mice compared with AAV5-LacZ-transduced mice. Oil red-O staining of the ascending aorta revealed that IL-10 gene transfer resulted in a 31% reduction in plaque surface area. Serum cholesterol concentrations were also significantly reduced in AAV5-mIL10-transduced mice. To understand the cholesterol-lowering mechanism of IL-10, we measured the cellular cholesterol level in HepG2 cells, resulting in its significant decrease by the addition of IL-10 in a dose-dependent manner. Furthermore, IL-10 suppressed HMG-CoA reductase expression in the HepG2 cells. These observations suggest that intramuscular injection of AAV5-mIL10 into ApoE-deficient mice inhibits atherogenesis through anti-inflammatory and cholesterol-lowering effects.
Asunto(s)
Apolipoproteínas E/deficiencia , Arteriosclerosis/prevención & control , Terapia Genética/métodos , Vectores Genéticos/genética , Interleucina-10/genética , Adenoviridae/genética , Animales , Aorta/metabolismo , Arteriosclerosis/inmunología , Arteriosclerosis/metabolismo , Arteriosclerosis/patología , Línea Celular , Quimiocina CCL2/metabolismo , Colesterol/metabolismo , Técnicas de Transferencia de Gen , Hidroximetilglutaril-CoA Reductasas/metabolismo , Interleucina-10/biosíntesis , Lípidos/sangre , Masculino , Ratones , Ratones Endogámicos C57BLRESUMEN
OBJECTIVE: To investigate a novel marker of oxidative stress in patients with congestive heart failure (CHF). PATIENTS: 15 patients with mild CHF, 15 patients with severe CHF with acute exacerbation, and 15 control subjects. MAIN OUTCOME MEASURES: Measurement of urinary 15-F2t-isoprostane, plasma brain natriuretic peptide (BNP), serum interleukin 6 (IL-6), and serum thrombomodulin concentrations. In patients with severe CHF, samples were taken at admission and 4, 7, and 14 days after admission. RESULTS: Urinary 15-F2t-isoprostane, plasma BNP, and serum IL-6 concentrations in patients with severe CHF were significantly higher than those in control subjects or in patients with mild CHF. However, concentrations of serum thrombomodulin, a marker of endothelial damage, were not different between patients with CHF and control subjects. In addition, urinary 15-F2t-isoprostane, plasma BNP, and serum IL-6 concentrations in patients with severe CHF gradually decreased in proportion to the severity of CHF during hospitalisation. Interestingly, urinary 15-F2t-isoprostane concentrations significantly correlated with plasma BNP concentrations and serum IL-6 concentrations, but not with serum thrombomodulin concentrations. CONCLUSIONS: Urinary 15-F2t-isoprostane concentrations increased in proportion to the severity of CHF in patients. This may be caused by increased 15-F2t-isoprostane production. These findings suggest that urinary 15-F2t-isoprostane may be a marker of morbidity as well as oxidative stress in patients with CHF.
Asunto(s)
F2-Isoprostanos/orina , Insuficiencia Cardíaca/etiología , Estrés Oxidativo/fisiología , Anciano , Anciano de 80 o más Años , Biomarcadores/orina , Femenino , Insuficiencia Cardíaca/orina , Humanos , Interleucina-6/sangre , Masculino , Persona de Mediana Edad , Péptido Natriurético Encefálico/sangre , Trombomodulina/sangreAsunto(s)
Factores de Crecimiento Endotelial/deficiencia , Insuficiencia Cardíaca/sangre , Péptidos y Proteínas de Señalización Intercelular/deficiencia , Linfocinas/deficiencia , Adulto , Anciano , Anciano de 80 o más Años , Factores de Crecimiento Endotelial/sangre , Femenino , Insuficiencia Cardíaca/etiología , Humanos , Péptidos y Proteínas de Señalización Intercelular/sangre , Linfocinas/sangre , Masculino , Persona de Mediana Edad , Factor A de Crecimiento Endotelial Vascular , Factores de Crecimiento Endotelial VascularRESUMEN
OBJECTIVE: Macrophage migration inhibitory factor (MIF), which plays a pivotal role in the control of inflammatory responses, was first characterized as a T-cell cytokine, but later was also found as a pituitary peptide released in response to infection and stress. However, MIF's role and expression in the myocardium has never been reported. The goal of this study is to examine MIF in the myocardium. METHODS AND RESULTS: MIF protein and mRNA levels were assayed using enzyme-linked immunosorbent assay (ELISA) and reverse transcription-polymerase chain reaction (RT-PCR), respectively. Increased MIF concentrations were detected in the sera of patients with acute myocardial infarction (AMI). In cultured rat cardiac myocytes, significant amounts of MIF were produced in response to hypoxia and hydrogen peroxide (H(2)O(2)), but not to angiotensin II, endothelin-1, interleukin-1beta (IL-1beta) or tumor necrosis factor alpha (TNFalpha). H(2)O(2)-induced MIF production increased in a time- and dose-dependent manner and was completely abolished in the presence of catalase. H(2)O(2) also induced MIF mRNA expression. The H(2)O(2)-induced MIF production was completely inhibited by the protein kinase C (PKC) inhibitor GF109203X, partially inhibited by the tyrosine kinase inhibitor herbimycin A, and uninhibited by calcium chelation or phorbol ester-sensitive PKC down-regulation. This suggests that H(2)O(2)-induced MIF production is mediated by an atypical PKC isoform. DNA microarray analysis revealed that 52 genes were preferentially expressed in response to MIF. Of these, the MIF-induced expression of both glutathione S-transferase (GST) and lipopolysaccharide-induced CXC chemokine (LIX) mRNAs was confirmed using RT-PCR analysis. CONCLUSION: The present results suggest that MIF is expressed by the myocardium in response to redox stress and may play a role in the pathogenesis of myocardial ischemia.
Asunto(s)
Factores Inhibidores de la Migración de Macrófagos/fisiología , Infarto del Miocardio/metabolismo , Miocardio/metabolismo , Análisis de Varianza , Animales , Benzoquinonas , Inhibidores Enzimáticos/farmacología , Ensayo de Inmunoadsorción Enzimática , Femenino , Regulación de la Expresión Génica , Humanos , Peróxido de Hidrógeno/farmacología , Indoles/farmacología , Lactamas Macrocíclicas , Factores Inhibidores de la Migración de Macrófagos/análisis , Factores Inhibidores de la Migración de Macrófagos/genética , Masculino , Maleimidas/farmacología , Persona de Mediana Edad , Infarto del Miocardio/sangre , Infarto del Miocardio/genética , Análisis de Secuencia por Matrices de Oligonucleótidos , Oxidación-Reducción , Proteína Quinasa C/antagonistas & inhibidores , Proteína Quinasa C/metabolismo , Quinonas/farmacología , ARN Mensajero/análisis , Ratas , Ratas Sprague-Dawley , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Rifabutina/análogos & derivadosAsunto(s)
Angioplastia Coronaria con Balón , Anticoagulantes/uso terapéutico , Administración Oral , Aspirina/uso terapéutico , Estenosis Coronaria/terapia , Cumarinas/uso terapéutico , Quimioterapia Combinada , Relación Normalizada Internacional , Trombosis/prevención & control , Factores de TiempoRESUMEN
The designation of atherosclerosis as a chronic inflammatory process represents an exciting and logical paradigm shift for cardiologists. Plasma concentrations of interleukin-6 (IL-6) and its hepatic by-product C-reactive protein (CRP) appear to reflect the intensity of occult plaque inflammation and by inference may determine vulnerability to rupture. Indeed, circulating IL-6 levels are elevated in patients with acute myocardial infarction (AMI), and also in patients with unstable, but not with stable angina. Coronary sinus IL-6 concentrations are also increased after percutaneous coronary intervention (PCI), and late restenosis correlates with an increase in IL-6 concentration after the procedure, indicating that IL-6 expression may be not only related to instability of atheromatous plaques, but also to the formation of restenotic lesions after PCI. These observations suggest the advantage of screening for circulating IL-6 concentration and the use of anti-inflammatory treatment for those thought be at high risk to reduce the risk of future AMI.
Asunto(s)
Enfermedad de la Arteria Coronaria/sangre , Interleucina-6/sangre , Angina de Pecho/sangre , Angioplastia Coronaria con Balón , Biomarcadores/sangre , Enfermedad de la Arteria Coronaria/tratamiento farmacológico , Reestenosis Coronaria/sangre , Humanos , Infarto del Miocardio/sangreRESUMEN
BACKGROUND: Peroxisome proliferator-activated receptors (PPARs) are transcription factors belonging to the nuclear receptor superfamily. PPARgamma mRNA is present in cardiac myocytes; however, whether PPARgamma affects cardiac hypertrophy remains unknown. METHODS AND RESULTS: We investigated the effects of PPARgamma activators on cardiac hypertrophy in neonatal rat cardiac myocytes. Cyclic 4% biaxial mechanical strain caused enlargement of cardiac myocytes (1.3-fold versus control, P<0.0001), but the PPARgamma activators troglitazone and 15-deoxy-Delta(12-14)-prostaglandin J(2) (15d-PGJ(2)) (10 micromol/L) inhibited this effect (troglitazone, -72%, P<0.0005; 15d-PGJ(2), -88%, P<0.0002). Total cell protein was increased by mechanical strain (control, 164.3 microgram/dish; strain, 265.5, P<0.0002), and this effect was inhibited by troglitazone and 15d-PGJ(2) (troglitazone, -61%, P<0.005; 15d-PGJ(2), -72%, P<0.001). [(3)H]Leucine uptake was also increased by mechanical strain (1.9-fold versus control, P<0.002), and this increase was inhibited by troglitazone and 15d-PGJ(2) (troglitazone, -52% at 10 micromol/L, P<0.01; 15d-PGJ(2), -70% at 10 micromol/L, P<0.005). An increase in [(3)H]leucine uptake induced by angiotensin II or phenylephrine was significantly inhibited by troglitazone and 15d-PGJ(2). Mechanical strain induced mRNA expression for brain natriuretic peptide, but PPARgamma activators inhibited this induction. Furthermore, PPARgamma activators inhibited mechanically induced activation of nuclear factor (NF)-kappaB. Pyrrolidine dithiocarbamate, an inhibitor of NF-kappaB activation, inhibited strain-induced [(3)H]leucine uptake (-50% at 100 micromol/L, P<0.05). CONCLUSIONS: These results demonstrate that PPARgamma activators inhibit cardiac hypertrophy in cardiac myocytes and suggest that PPARgamma activators may regulate cardiomyocyte hypertrophy at least partially through the NF-kappaB pathway.
Asunto(s)
Cardiomegalia/etiología , Cromanos/farmacología , Miocardio/citología , Prostaglandina D2/farmacología , Receptores Citoplasmáticos y Nucleares/metabolismo , Tiazoles/farmacología , Tiazolidinedionas , Factores de Transcripción/metabolismo , Angiotensina II/farmacología , Animales , Animales Recién Nacidos , Transporte Biológico , Cardiomegalia/metabolismo , Cardiomegalia/patología , Células Cultivadas , Corazón/efectos de los fármacos , Leucina/metabolismo , Miocardio/metabolismo , FN-kappa B/metabolismo , Péptido Natriurético Encefálico/biosíntesis , Péptido Natriurético Encefálico/genética , Fenilefrina/farmacología , Prostaglandina D2/análogos & derivados , ARN Mensajero/biosíntesis , Ratas , Estrés Mecánico , TroglitazonaAsunto(s)
Proteína C-Reactiva/análisis , Enfermedad Coronaria/inmunología , Inhibidores de Hidroximetilglutaril-CoA Reductasas/farmacología , Interleucina-6/biosíntesis , Reacción de Fase Aguda , Arteriosclerosis/inmunología , Enfermedad Coronaria/prevención & control , Humanos , Inhibidores de Hidroximetilglutaril-CoA Reductasas/uso terapéutico , Interleucina-6/análisisAsunto(s)
Fibrilación Atrial/etiología , Prolapso de la Válvula Mitral/complicaciones , Fibrilación Atrial/diagnóstico por imagen , Ecocardiografía Doppler en Color , Femenino , Humanos , Modelos Logísticos , Masculino , Persona de Mediana Edad , Prolapso de la Válvula Mitral/diagnóstico por imagen , Factores de RiesgoAsunto(s)
Inhibidores de la Enzima Convertidora de Angiotensina/uso terapéutico , Oclusión de Injerto Vascular/prevención & control , Factor Estimulante de Colonias de Macrófagos/efectos de los fármacos , Perindopril/uso terapéutico , Genotipo , Humanos , Infarto del Miocardio/tratamiento farmacológicoRESUMEN
We investigated whether nitric oxide (NO) synthase gene transfer could attenuate growth of cultured cardiac myocytes. First, we investigated the effects of exogenous NO and cGMP analog on protein synthesis of cultured neonatal rat cardiac myocytes. The NO donor 3-morpholino-sydnonimine-hydrochloride (SIN-1) and 8-bromo-cGMP caused concentration-dependent decreases in phenylephrine-stimulated incorporation of 3H-leucine into cardiac myocytes. We then transferred endothelial constitutive NO synthase (ecNOS) gene into cultured neonatal rat cardiac myocytes using adeno-associated virus (AAV) vectors. ecNOS gene transfer into cardiac myocytes induced 140 kD ecNOS protein expression and significantly increased cGMP contents of myocytes compared with control cells. ecNOS gene transfer inhibited 3H-leucine incorporation into cardiac myocytes in response to phenylephrine, which was significantly recovered in the presence of the NOS inhibitor N(G)-monomethyl-L-arginine acetate. These results indicate that endogenously generated NO by ecNOS gene transfer using AAV vectors inhibits the alpha-adrenergic agonist-induced cardiac protein synthesis at least partially via cGMP production.
Asunto(s)
Adenoviridae/genética , GMP Cíclico/análogos & derivados , Proteínas Musculares/biosíntesis , Miocardio/metabolismo , Óxido Nítrico Sintasa/genética , Agonistas alfa-Adrenérgicos/farmacología , Animales , GMP Cíclico/biosíntesis , GMP Cíclico/farmacología , Inhibidores Enzimáticos/farmacología , Vectores Genéticos , Ventrículos Cardíacos/citología , Ventrículos Cardíacos/efectos de los fármacos , Ventrículos Cardíacos/metabolismo , Immunoblotting , Leucina/metabolismo , Miocardio/citología , Óxido Nítrico Sintasa/antagonistas & inhibidores , Óxido Nítrico Sintasa de Tipo III , Fenilefrina/farmacología , Plásmidos/genética , Ratas , omega-N-Metilarginina/farmacologíaRESUMEN
We describe a 72-year-old woman with hypertension who developed acute neurogenic pulmonary edema and giant negative T waves on electrocardiography (ECG) due to subarachnoid hemorrhage. The patient was alert and complained of precordial chest discomfort, dyspnea and shoulder stiffness. Echocardiography demonstrated normal left ventricle contraction with hypertrophy. Computed tomography (CT) and subsequent cerebral angiography revealed subarachnoid hemorrhage and saccular aneurysm at the anterior communicating artery. It is important to consider the possibility of subarachnoid hemorrhage when a patient shows pulmonary edema and ECG abnormalities even without typical clinical signs of subarachnoid hemorrhage.
Asunto(s)
Edema Pulmonar/etiología , Hemorragia Subaracnoidea/complicaciones , Hemorragia Subaracnoidea/diagnóstico , Anciano , Diagnóstico Diferencial , Electrocardiografía , Femenino , Humanos , Edema Pulmonar/fisiopatología , Hemorragia Subaracnoidea/fisiopatología , Tomografía Computarizada por Rayos XRESUMEN
Nitric oxide production by inducible nitric oxide synthase (iNOS) may play an important role in the pathogenesis of cardiovascular dysfunction. We investigated the effects of statins on iNOS expression and subsequent nitric oxide synthesis in cardiac myocytes and the mechanism by which statins exert their effects. We measured the production of nitrite, a stable metabolite of nitric oxide, in cultured neonatal rat cardiac myocytes with the Griess reagent. iNOS mRNA and protein expression were assayed by reverse transcription polymerase chain reaction and Western blotting, respectively. The lipophilic statins fluvastatin and lovastatin significantly increased interleukin-1beta-induced nitrite production by cardiac myocytes, whereas hydrophilic pravastatin did not. Increased nitrite production by fluvastatin was accompanied by increased iNOS mRNA and protein accumulation. Exogenous mevalonate, but not squalene, significantly blocked the stimulatory effect of fluvastatin on nitrite production. Cotreatment with geranylgeranyl-pyrophosphate also reversed the effect of fluvastatin. Furthermore, both Rho inhibitor C3 exoenzyme and Rho kinase inhibitor Y-27632 significantly increased interleukin-1beta-induced nitrite accumulation in cardiac myocytes. These results demonstrated that lipophilic statins upregulate iNOS expression and subsequent nitric oxide formation in cardiac myocytes via inhibition of Rho.